Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
279.9 GBX | +1.05% |
|
-0.74% | -1.09% |
06-25 | Takeda's Cancer Drug Gets European Commission Approval | MT |
06-24 | Hutchmed China notes Takeda obtains EU approval for Fruzaqla | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.09% | 2.99B | |
+55.95% | 819B | |
+43.42% | 638B | |
-6.98% | 351B | |
+19.08% | 329B | |
+9.05% | 298B | |
+16.96% | 242B | |
+2.86% | 225B | |
+13.30% | 217B | |
+8.91% | 168B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment